EUVIMEDSkopri EUVIMED
LeserbriefOpen access · CC BY-NC-ND 4.0

A novel calcipotriol and betamethasone dipropionate ( CAL / BDP ) PAD ‐cream demonstrates greater improvements in daily activities and personal relationships than CAL / BDP gel/ TS : A post‐hoc analysis of DLQI outcomes from two phase 3 placebo‐controlled randomized clinical trials in mild‐to‐moderate psoriasis

B Halioua iD, G Caillet, C Taieb iD, A Bewley, A Snel-Prentø, M Praestegaard, A Armstrong, A Pinter iD

Journal of the European Academy of Dermatology and Venereology · 2024

DOI: 10.1111/jdv.19600 ↗

At a glance

Leserbrief in Journal of the European Academy of Dermatology and Venereology, 2024. Written by B Halioua and 7 co-authors. Institution: Private, Dermatologist, Paris, France. Major MEDLINE topics: Betamethasone, Calcitriol, Dermatologic Agents, Psoriasis. Cited 3 times so far (Crossref); 7 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: MC2 Therapeutics.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Ebda abstract disponibbli.

Subjects

MeSH terms (MEDLINE)

BetamethasoneCalcitriolDermatologic AgentsPsoriasisHumansDrug CombinationsRandomized Controlled Trials as TopicTreatment OutcomeClinical Trials, Phase III as Topic

Substances

Betamethasonebetamethasone-17,21-dipropionatecalcipotrieneCalcitriolDermatologic AgentsDrug Combinations

Authors and institutions

  • Private, Dermatologist, Paris, France.
  • Almirall, Paris, France.
  • EMMA, Patients Priority, Fontenay Sous-Bois, France.
  • Department of Dermatology, Barts Health NHS Trust & Queen Mary University, London, UK.
  • MC2 Therapeutics, A/S, Hørsholm, Denmark.
  • University of Southern California, Los Angeles, San Francisco, California, USA.

ORCID profiles: B Halioua, C Taieb, A Pinter

Funding

  • MC2 Therapeutics

Cite

APA

Halioua, B., Caillet, G., Taieb, C., Bewley, A., Snel-Prentø, A., Praestegaard, M., Armstrong, A., & Pinter, A. (2024). A novel calcipotriol and betamethasone dipropionate ( CAL / BDP ) PAD ‐cream demonstrates greater improvements in daily activities and personal relationships than CAL / BDP gel/ TS : A post‐hoc analysis of DLQI outcomes from two phase 3 placebo‐controlled randomized clinical trials in mild‐to‐moderate psoriasis. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19600

Vancouver

Halioua B, Caillet G, Taieb C, Bewley A, Snel-Prentø A, Praestegaard M, et al. A novel calcipotriol and betamethasone dipropionate ( CAL / BDP ) PAD ‐cream demonstrates greater improvements in daily activities and personal relationships than CAL / BDP gel/ TS : A post‐hoc analysis of DLQI outcomes from two phase 3 placebo‐controlled randomized clinical trials in mild‐to‐moderate psoriasis. Journal of the European Academy of Dermatology and Venereology. 2024. doi:10.1111/jdv.19600

BibTeX
@article{Halioua2024,
  author = {Halioua, B and Caillet, G and Taieb, C and Bewley, A and Snel-Prentø, A and Praestegaard, M and Armstrong, A and Pinter, A},
  title = {A novel calcipotriol and betamethasone dipropionate ( CAL / BDP ) PAD ‐cream demonstrates greater improvements in daily activities and personal relationships than CAL / BDP gel/ TS : A post‐hoc analysis of DLQI outcomes from two phase 3 placebo‐controlled randomized clinical trials in mild‐to‐moderate psoriasis},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2024},
  doi = {10.1111/jdv.19600}
}
Start for free →